Literature DB >> 20055785

Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease.

G A Doherty1, G C Bennett, A S Cheifetz, A C Moss.   

Abstract

BACKGROUND: Enteric bacteria play an important early role in the pathogenesis of Crohn's disease. AIM: To perform a meta-analysis of trials testing antibiotics or probiotics for prevention of post-operative recurrence of Crohn's disease.
METHODS: Review of all randomized controlled trials comparing antibiotics or probiotics with placebo in prevention of endoscopic or clinical recurrence of Crohn's disease after surgical resection. Fixed-effect meta-analysis was performed with dichotomous data summarized using relative risk with 95% confidence intervals, where appropriate.
RESULTS: Seven studies were identified as suitable for inclusion (two comparing antibiotics with placebo, five comparing probiotics with placebo). The use of nitroimidazole antibiotics (metronidazole, ornidazole) reduced the risk of clinical (RR 0.23; 95% CI 0.09-0.57, NNT = 4) and endoscopic (RR 0.44; 95% CI 0.26-0.74, NNT = 4) recurrence relative to placebo. However, these agents were associated with higher risk of adverse events (RR 2.39, 95% CI 1.5-3.7) and patient withdrawal. Probiotic administration was not associated with any significant difference in risk of recurrence compared with placebo.
CONCLUSIONS: Nitroimidazole antibiotics are effective in the prevention of post-operative Crohn's disease recurrence, but their side-effects limit acceptability. Probiotics have failed to show efficacy for post-operative prophylaxis, but may merit further study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20055785     DOI: 10.1111/j.1365-2036.2010.04231.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  [New therapeutic approaches to special diseases of the small intestine].

Authors:  M Schumann; K Herrlinger; M Zeitz; E F Stange
Journal:  Internist (Berl)       Date:  2010-06       Impact factor: 0.743

2.  Probiotics in Colorectal Surgery.

Authors:  Robert Martindale; Malissa Warren; Vassiliki L Tsikitis
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

Review 3.  Pathway-based approaches to the treatment of inflammatory bowel disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Transl Res       Date:  2015-09-07       Impact factor: 7.012

4.  A survey of current practices used to maintain surgically induced remission following intestinal resection for Crohn's disease.

Authors:  John P Burke; Glen A Doherty; P Ronan O'Connell
Journal:  Int J Colorectal Dis       Date:  2013-03-09       Impact factor: 2.571

5.  The human microbiome and surgical disease.

Authors:  Michael J Morowitz; Trissa Babrowski; Erica M Carlisle; Andrea Olivas; Kathleen S Romanowski; John B Seal; Donald C Liu; John C Alverdy
Journal:  Ann Surg       Date:  2011-06       Impact factor: 12.969

6.  Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches.

Authors:  Jonathan J Hansen; R Balfour Sartor
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

7.  Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease.

Authors:  Byron P Vaughn; Tommi Vatanen; Jessica R Allegretti; Aiping Bai; Ramnik J Xavier; Joshua Korzenik; Dirk Gevers; Amanda Ting; Simon C Robson; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

Review 8.  Antibiotics and probiotics in inflammatory bowel disease: when to use them?

Authors:  Bincy Abraham; Eamonn M M Quigley
Journal:  Frontline Gastroenterol       Date:  2019-03-22

Review 9.  Preventing postoperative recurrence in Crohn's disease: what does the future hold?

Authors:  Lucine Vuitton; Stéphane Koch; Laurent Peyrin-Biroulet
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 10.  Pharmacological Prevention and Management of Postoperative Relapse in Pediatric Crohn's Disease.

Authors:  Anat Yerushalmy-Feler; Amit Assa
Journal:  Paediatr Drugs       Date:  2019-12       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.